Antibody Response Post-COVID-19 Vaccination in Patients With Chronic Myeloid Leukemia With Comparison Between Comirnaty and CoronaVac Vaccine

• Main Authors: Kuan, Jew Win, Tan, Cheng Siang, Anselm, Su Ting, Vaenessa, Noni, Whilemena Upam, Herman Ulok Melina, Ummi Syafiqah, Abdorahman, Joseph Niler, Bimbang, Lela, Suut, Asri, Said
• Format: Article
• Language: English
• Published: SAGE Publications Inc. 2022
• Subjects: R Medicine (General); RC Internal medicine; RC0254 Neoplasms. Tumors. Oncology (including Cancer); RZ Other systems of medicine
• Online Access: http://ir.unimas.my/id/eprint/38986/1/Antibody%20Response%20Post-COVID-19%20Vaccination%20in%20Patients%20With%20Chronic%20Myeloid%20Leukemia%20With%20Comparison%20Between%20Comirnaty%20and%20CoronaVac%20Vaccine.pdf; http://ir.unimas.my/id/eprint/38986/; https://journals.sagepub.com/doi/abs/10.1177/10105395221112836?journalCode=apha
• Institution: Universiti Malaysia Sarawak

Dear Editor Chronic myeloid leukemia (CML) is a type of myeloproliferative neoplasm characterized by an oncogenic fusion gene, BCR-ABL1. Most CML patients present at chronic phase, ~90%,1 when BCR-ABL1 tyrosine kinase inhibitor (TKI) is the recommended first-line treatment. Antibody response afte...